Avalo Therapeutics, Inc. (AVTX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -17.69M | -14.25M | -16.36M | -11.39M | -9.46M | -15.04M | -11.53M | -16.28M | -6.2M | -2.77M | -6.84M | -11.03M |
| Operating CF Margin % | - | -24145.76% | - | - | - | -7835.42% | -4629.32% | - | - | -484.41% | -2896.61% | -1714.77% |
| Operating CF Growth % | -87.07% | 5.3% | -41.97% | 30.05% | -52.48% | -443.89% | -68.62% | -47.68% | 38.3% | 29.8% | -219.39% | 11.58% |
| Net Income | -19.63M | -13.72M | -30.63M | -20.77M | -13.15M | -35.34M | 23.04M | 98.46M | -121.29M | -8.17M | -5.23M | -8.19M |
| Depreciation & Amortization | 17K | 16K | 59K | 134K | 135K | 68K | 34K | 33K | 34K | 43K | 41K | 41K |
| Stock-Based Compensation | 3.58M | 4.51M | 3.15M | 0 | 3.24M | 2.9M | 1.85M | 471K | 629K | 0 | 953K | 893K |
| Deferred Taxes | 12K | 131K | 10K | 16K | -501K | 114K | -14K | 7K | 7K | -9K | 8K | 7K |
| Other Non-Cash Items | -586K | -5.36M | 12.18M | 5.61M | -380K | 17.82M | -34.92M | -113.93M | 115.68M | 5.28M | 1.03M | 389K |
| Working Capital Changes | -1.08M | 176K | -1.15M | 3.61M | 1.2M | -612K | -1.51M | -1.33M | -1.26M | 85K | -3.64M | -4.16M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 387K | -965K | 2K | 101K | 1.4M | 38K | 813K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18K | 1K |
| Change in Payables | 219K | -337K | -1.89M | 1.69M | 398K | -1.53M | 1.16M | -262K | 470K | -342K | 37K | -4.81M |
| Cash from Investing | 25.5M | 2.4M | -13.26M | -70.86M | 0 | 0 | 0 | 0 | 356K | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -158K | 0 | 158K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 27.67% | - | 24.57% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 356K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 106K | 197K | 10.5M | 0 | 0 | 0 | 0 | 0 | 0 | 158K | 0 | -158K |
| Cash from Financing | 1.4M | 687K | 14.37M | -469K | 0 | 67.71M | 0 | -472K | 108.61M | 1K | 10.7M | 598K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15.24M | 0 |
| Equity Issued (Net) | 2.18M | 687K | 14.37M | 40K | 0 | 185.07M | 0 | 0 | 115.63M | 1K | 25.94M | 6.53M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -779K | 0 | -1K | -509K | 0 | -117.36M | 0 | -472K | -7.01M | 0 | 0 | -5.93M |
| Net Change in Cash | 9.21M | -11.16M | -15.26M | -82.8M | -9.46M | 52.67M | -11.53M | -16.75M | 102.77M | -2.77M | 3.86M | -10.43M |
| Free Cash Flow | -17.69M | -14.25M | -16.36M | -11.39M | -9.46M | -15.04M | -11.53M | -16.28M | -6.2M | -2.92M | -6.84M | -11.03M |
| FCF Margin % | - | -24145.76% | - | - | - | -7835.42% | -4629.32% | - | - | -512.08% | -2896.61% | -1714.77% |
| FCF Growth % | -87.07% | 5.3% | -41.97% | 30.05% | -52.48% | -414.5% | -68.62% | -47.68% | 38.3% | 26.83% | -220.2% | 11.98% |
| FCF per Share | -0.88 | -0.77 | -1.17 | -1.05 | -0.90 | -1.44 | -1.07 | -2.13 | -7.22 | -3.65 | -35.08 | -189.40 |
| FCF Conversion (FCF/Net Income) | 0.90x | 1.04x | 0.53x | 0.55x | 0.72x | 0.43x | -0.50x | -0.17x | 0.05x | 0.34x | 1.31x | 1.35x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 735K |
| Taxes Paid | 0 | 0 | 0 | 0 | 509K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |